Quantcast

Latest iPierian Inc. Stories

2010-09-30 07:30:00

SOUTH SAN FRANCISCO, Calif., Sept. 30 /PRNewswire/ -- iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced that it has appointed Michael P. Smith as Vice President, Business Development and Wayne Montgomery, J.D., as Vice President, Legal Affairs and Intellectual Property. "Mike brings to iPierian a breadth of strategic and transactional experience at both small and large companies. This...

2010-09-15 07:00:00

SOUTH SAN FRANCISCO, Calif., Sept. 15 /PRNewswire/ -- iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced that FierceBiotech has named iPierian as one of 2010's Fierce 15, designating it as one of the most promising biotech companies in the industry. Every year FierceBiotech evaluates hundreds of private companies for its annual list, which is based on a variety of factors such as the...

2010-09-08 07:30:00

SOUTH SAN FRANCISCO, Calif., Sept. 8 /PRNewswire/ -- iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced the second closing of its Series B equity financing, bringing the total amount raised in this round to $28 million. SR One, the independent corporate healthcare venture capital arm of GlaxoSmithKline, Biogen Idec New Ventures, and additional undisclosed investors participated in this...

2010-07-08 08:06:00

SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire/ -- iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced the closing of a $22 million Series B equity financing. The financing round was led by new investor Google Ventures, and was joined by Mitsubishi UFJ Capital and ATEL Ventures. All current investors also participated, including: Kleiner Perkins Caufield & Byers, Highland Capital...

2010-06-15 09:24:00

SOUTH SAN FRANCISCO, Calif., June 15 /PRNewswire/ -- iPierian, Inc., the leading biopharmaceutical company focused on creating new therapeutics using patient-derived induced pluripotent stem cells (iPSCs), today announced that it will present data from its iPSC research programs at the International Society for Stem Cell Research (ISSCR) 8th Annual Meeting, June 16-19, 2010, in San Francisco, CA. Data presented in a poster entitled, Discovery of disease gene expression signature in...

2010-04-29 15:20:00

SOUTH SAN FRANCISCO, Calif., April 29 /PRNewswire/ -- iPierian, Inc., the leading company focused on creating new therapeutics discovered using cellular reprogramming and directed differentiation of patient cells, today announced that it has been awarded a three-year $1.5 million "Basic Biology Award" from the California Institute of Regenerative Medicine (CIRM). The grant will be used to fund the study of mechanisms of cellular reprogramming with the specific aim of enhancing the...

2010-02-23 07:00:00

SOUTH SAN FRANCISCO, Calif., Feb. 23 /PRNewswire/ -- iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced the appointment of Michael C. Venuti, Ph.D., as president and chief scientific officer. "A major goal for iPierian over the next five years is to develop drug candidates, both on its own and through partnerships, based on the application of cellular...

2010-01-28 07:00:00

SOUTH SAN FRANCISCO, Calif., Jan. 28 /PRNewswire/ -- iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced that the Intellectual Property Office in the United Kingdom has issued a Notification of Grant to iPierian for UK patent No. GB2450603, its first patent related to induced pluripotent stem cell (iPSC) technology. The newly granted UK patent covers the...

2009-10-21 11:00:00

SOUTH SAN FRANCISCO, Calif., Oct. 21 /PRNewswire/ -- iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced that it has been selected to participate in a $3.7 million National Institutes of Health (NIH) Grand Opportunities (GO) grant awarded to The Johns Hopkins University. The grant, given over a two-year span, will be used to generate amyotrophic lateral sclerosis...

2009-09-01 07:30:00

SOUTH SAN FRANCISCO, Calif., Sept. 1 /PRNewswire/ -- iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced the appointment of Matthew J. Plunkett, Ph.D., as vice president and chief financial officer. "Capital formation is critical to our long term success, and Matt's career over the last decade has given him the experience and network to help position iPierian with...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.